Study of Combined Endocrine, Chemotherapy, and HER2 Targeted Treatment in Adults with HER2 Positive Hormone Receptor Positive Breast Cancer

What this Trial Is About

Researchers are evaluating whether adding endocrine therapy to the usual chemotherapy and HER2-targeted therapy before surgery can improve treatment response in adults with hormone receptor-positive, HER2-positive breast cancer. This phase 2 study focuses on breast cancer patients who have not yet received treatment and aims to see if this combination increases the effectiveness of therapy at the time of surgery. Participants will receive concurrent endocrine therapy along with chemotherapy and HER2-directed therapy as part of their treatment before surgery. The choice of endocrine therapy will be decided by their physician, and it must begin before the second cycle of chemotherapy and HER2 therapy. The study includes patients with stage IIA to IIIC breast cancer who will undergo at least four cycles of TCHP chemotherapy. During the study, researchers will monitor participants for pathological complete response rates 21 months after treatment begins and assess residual cancer burden scores as a secondary outcome. Participants will be followed over this period to evaluate their response to therapy. Safety and treatment effects will be observed throughout, with ongoing assessments to understand how well the combined therapies work together.

Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer